Aura Biosciences Stock (NASDAQ:AURA)

Forecast Revenue Ownership Financials Chart

Previous Close

$6.51

52W Range

$4.34 - $9.04

50D Avg

$5.94

200D Avg

$6.24

Market Cap

$414.67M

Avg Vol (3M)

$260.00K

Beta

0.44

Div Yield

AURA Company Profile

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

106

IPO Date

Oct 29, 2021

Website

AURA Performance

AURA Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	-	$-84.99M	$-60.30M
Net Income	$-86.92M	$-76.41M	$-57.23M
EBITDA	-	$-83.70M	$-59.12M
Basic EPS	$-1.75	$-1.93	$-1.91
Diluted EPS	$-1.75	$-1.93	$-1.91

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
LBRX	LB Pharmaceuticals Inc Common Stock
QSI	Quantum-Si incorporated
DSGN	Design Therapeutics, Inc.
ALT	Altimmune, Inc.
ANNX	Annexon, Inc.
ENGN	enGene Holdings Inc.
SLDB	Solid Biosciences Inc.
RCKT	Rocket Pharmaceuticals, Inc.
DBVT	DBV Technologies S.A.
KRRO	Korro Bio, Inc.